← Evidence map

TrialScientific reports2025

Immunogenicity and safety of CoronaVac vaccine in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow up.

Camila Amormino Corsini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Immunogenicity and safety of CoronaVac vaccine in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow up. | OpenQuestion